ZFGN Zafgen Inc.

5.17
-0.17  -3%
Previous Close 5.34
Open 5.27
Price To Book 1.83
Market Cap 190621933
Shares 36,870,780
Volume 142,102
Short Ratio
Av. Daily Volume 321,551

SEC filingsSee all SEC filings

  1. 8-K - Current report 181199948
  2. EFFECT - Notice of Effectiveness 181196911
  3. 8-K - Current report 181173951
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181173722
  5. S-3 - Registration statement under Securities Act of 1933 181173701

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 additional data due early 2019.
ZGN-1061
Diabetes
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity
Announced July 2016 suspension of development of Beloranib
Beloranib
Prader-Willi Syndrome (PWS)
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity

Latest News

  1. Ghost Tree Capital’s AUM, Returns and Holdings
  2. CURRENT SHAREHOLDERS: Zamansky LLC Investigates Zafgen (ZFGN) for Potential Breaches of Fiduciary Duties
  3. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investigation of Zafgen, Inc. (ZFGN)
  4. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zafgen, Inc. – ZFGN
  5. Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News
  6. Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial
  7. Zafgen: Bargain or Busted?
  8. Company News For Nov 27, 2018
  9. Today's Research Reports on Trending Tickers: Zafgen and Edge Therapeutics
  10. Why Aurora Cannabis, Zafgen, and Overstock.com Slumped Today
  11. Why Zafgen Stock Is Crashing Today
  12. Zafgen shares cut in half after FDA halts diabetes drug trial
  13. U.S. FDA puts Zafgen's diabetes trial on hold
  14. Zafgen's IND for diabetes treatment placed on hold by FDA
  15. Zafgen Provides Update on Investigational New Drug Application for ZGN-1061
  16. Zafgen to Present at the 30th Annual Piper Jaffray Healthcare Conference
  17. Edited Transcript of ZFGN earnings conference call or presentation 7-Nov-18 9:30pm GMT
  18. Zafgen Reports Third Quarter 2018 Operating and Financial Results

SEC Filings

  1. 8-K - Current report 181199948
  2. EFFECT - Notice of Effectiveness 181196911
  3. 8-K - Current report 181173951
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181173722
  5. S-3 - Registration statement under Securities Act of 1933 181173701
  6. S-8 - Securities to be offered to employees in employee benefit plans 181173671
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173505
  8. 8-K - Current report 181166506
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181007633
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005551